• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY: MRK )

    125.80 +1.55 (+1.25%)
    Streaming Delayed Price Updated: 2:05 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    87 88 Next >
    Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
    Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
    Via Talk Markets
    Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
    Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly... 
    Via Benzinga
    Smart Money Is Betting Big In MRK Options
    Via Benzinga
    Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
    Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal. 
    Via Investor's Business Daily
    FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
    From Merck & Co., Inc.
    Via Business Wire
    MERCK & CO. INC. (NYSE:MRK) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
    Exploring MERCK & CO. INC.'s Technical Signals and Breakout Potential. 
    Via Chartmill
    Performance Comparison: Merck &amp; Co And Competitors In Pharmaceuticals Industry
    Via Benzinga
    Merck to Acquire EyeBio
    From Merck & Co., Inc.
    Via Business Wire
    No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
    It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse. 
    Via InvestorPlace
    Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence
    Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing... 
    Via Benzinga
    Merck Announces Third-Quarter 2024 Dividend
    From Merck & Co., Inc.
    Via Business Wire
    Check Out What Whales Are Doing With MRK
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Lung Cancer Study
    Merck's KEYNOTE-522 trial shows Keytruda combined with chemotherapy significantly improves overall survival in high-risk early-stage triple-negative breast cancer patients compared to chemotherapy... 
    Via Benzinga
    Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
    From Merck & Co., Inc.
    Via Business Wire
    When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    For those who appreciate value investing, MERCK & CO. INC. (NYSE:MRK) is a compelling option with its solid fundamentals. 
    Via Chartmill
    AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
    Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers. 
    Via Benzinga
    S&P 500 Plays And One Dow Jones Giant Lead Five Stocks Near Buy Points
    These five names are showing relative strength. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
    Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with... 
    Via Benzinga
    Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
    The company passed investors' bar for success in a study of a head-and-neck cancer treatment. 
    Via Investor's Business Daily
    Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?
    The billionaire hedge fund manager doesn't need dividend income. But he'll get more of it after his Q1 purchases. 
    Via The Motley Fool
    Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day
    Summer has arrived on Wall Street! Discover three cheap stocks to buy with solid fundamentals to boost your profitability this season. 
    Via InvestorPlace
    Large Cap Biopharmaceuticals Performance
    The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
    Via Talk Markets
    5 Stocks Powering The Dow ETF Year To Date
    While most of the stocks in the ETF portfolio have been rising this year, these five that have been leading the way higher. 
    Via Talk Markets
    Topics ETFs Stocks
    Exposures US Equities
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches
    With the market potentially posing some challenges, investors may find comfort in considering these safe haven stocks to buy. 
    Via InvestorPlace
    Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
    It depends on what your goals, objectives, and risk tolerances are. 
    Via Talk Markets
    Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
    On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
    From Merck & Co., Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    87 88 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.